Combined doses of dipyridamole and ASA achieved maximum reductions in platelet functions without prolonging bleeding time, demonstrating a synergistic effect at lower doses.
Do varying combined doses of dipyridamole and acetylsalicylic acid inhibit platelet function without prolonging bleeding time in normal volunteers?
Low-dose combinations of dipyridamole and ASA maximally inhibit platelet function without altering bleeding time, suggesting potential utility for clinical trials.
1 In normal volunteers maximum reductions in platelet functions, collagen aggregation, adhesion and PF4 availability, were achieved using combined doses of 50 mg three times daily dipyridamole + 180 mg ASA or 75 mg three times daily dipyridamole + 120 mg ASA daily. 2 These doses did not prolong the bleeding time. 3 A synergistic effect has been demonstrated with 25 mg dipyridamole three times daily and 60 mg ASA. 4 At higher doses the effects on platelet functions were additive up to the maximal response. 5 The effect of low doses of ASA on platelet function was cumulative. 6 As lower doses of ASA in the combination studied inhibit platelet functions maximally without altering the bleeding time and probably without inhibiting prostacyclin, we suggest that these combinations of dipyridamole and ASA merit consideration in future clinical trials.
Rajah et al. (Thu,) conducted a other in Healthy volunteers. Dipyridamole and acetyl salicylic acid (ASA) was evaluated on Platelet functions (collagen aggregation, adhesion, PF4 availability) and bleeding time. Combined doses of dipyridamole and ASA achieved maximum reductions in platelet functions without prolonging bleeding time, demonstrating a synergistic effect at lower doses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: